Ocular Therapeutix, Inc. provided earnings guidance for the fiscal year 2022. For the period, the company expects total net product revenue to be in the range of $48 to $52 million, representing growth of between 10% to 20% over 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6 USD | -1.64% | -4.61% | +34.53% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.53% | 945M | |
+37.74% | 723B | |
+32.22% | 598B | |
-2.07% | 364B | |
+20.25% | 331B | |
+2.99% | 288B | |
+16.60% | 244B | |
+9.77% | 210B | |
-5.15% | 208B | |
+7.43% | 169B |
- Stock Market
- Equities
- OCUL Stock
- News Ocular Therapeutix, Inc.
- Ocular Therapeutix, Inc. Provides Earnings Guidance for the Fiscal Year 2022